Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)

Completed · Not applicable

Conditions studied: Prostate Cancer

In brief

This is a prospective outcomes study assessing quality of life and oncological control at pre-defined time points following FOCAL CRYO-ABLATION (FCA). The investigator's standard of care is to perform an Magentic Resonance Imaging (MRI) and prostate biopsy two years following FCA. The prostate biopsy assesses both the presence of in field and out of field disease. The role of Axumin PET/MRI for detecting disease following FCA has not been previously examined.

Key facts

Study ID

NCT04009083

Run by

NYU Langone Health

People needed

31

Starts

2019-06-19

Expected to finish

2021-01-07

Last updated by the study team

2021-03-30

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• FCA at NYU Langone Health performed at least two years prior to study enrollment by Drs. Lepor or Wysock.
• No prostate cancer specific treatment following FCA
• Consented to undergo reflex MRI and prostate biopsy two years following FCA.

You may not qualify if…

• Any contraindication to prostate biopsy
• Prior allergic reaction to 18F-Fluciclovine
• Patient refuses MRI and prostate biopsy two years following FCA.

Where it is running

• NYU Langone Health — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.